Europe’s “divisional patent” trap is one of those legal mechanisms that sounds technical—until you see what it does to patients, payers, and timelines.
Here’s the uncomfortable truth: Big Pharma can often delay generic entry without “losing in court.” …
Generic drugs are no longer “copy-and-ship.” They’re precision engineering—and the winners know exactly how to prove it.
If you’re building a complex generic, you already feel the pressure: the science is harder, the timelines are tighter, and regula…
Cracking Complex Generics: The Bioequivalence Playbook That Gets ANDAs Approved Read Post »
Pharma is in a talent race—and most teams are playing it like a guessing game.
The “patent clock” is ticking whether you’re ready or not. In drug development, timing isn’t just about science. It’s about people: the inventors, the legal minds, the techn…
The Patent Clock: How to Find Pharma’s Best Talent Before They Know They’re Looking Read Post »
Pharma patent litigation is often sold as a legal problem.
But in practice, it’s a business tax—one that hits revenue, cash flow, and strategic optionality long before a court ever issues a ruling.
The legal bills are visible. The real costs are usuall…
What Pharma Patent Litigation Actually Costs (It’s Not the Legal Bills) Read Post »
Australia’s “drug patent clock” sounds simple—until you look under the hood.
For years, the public narrative has been that patents provide a clean, predictable runway for innovation: file a patent, get protection, earn returns, and eventually generics …
Australia’s Drug Patent Clock: The Complete Guide to How Long Protection Actually Lasts Read Post »
Pharma’s “reformulation playbook” is getting a lot of attention for a reason: it’s one of the few strategies that can simultaneously extend exclusivity, delay generic entry, and reset pricing power—often without the kind of breakthrough innovation pati…
Drug spend is not a mystery problem. It’s a timing problem.
If you’re responsible for pharmacy budgets—whether you’re in procurement, payer strategy, or health systems—there’s a moment every year when the math stops working. Formularies get tighter. Ut…
Patent Expiration Data: The Procurement Playbook That Cuts Your Drug Spend by 80% Read Post »
The Drug Patent Cliff Isn’t a “Legal” Problem—It’s a Procurement Problem.
If you manage sourcing, budgets, or supplier performance, you already know the uncomfortable truth: the next wave of generic and biosimilar competition won’t arrive with a memo. …
The Drug Patent Cliff: A Procurement Manager’s Sourcing Playbook Read Post »
The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Can Imperil Sponsor Patents
Clinical development is already a high-wire act—timelines, trial execution, regulatory scrutiny, and data integrity. But there’s a quieter risk that’s sta…
Generic drug decisions in New Zealand aren’t just about science—they’re about timing, law, and a single hard deadline.
If you’ve ever watched a generic launch get delayed, you know the pattern: not one big surprise, but a chain of smaller ones—regulato…
Get new actionable insights and updates from BiotechBlog
